Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameInnovent Bio
Stock Code01801
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities开发并销售老百姓能买得起的优质药物,拥有全面集成的生物医药平台,专注于肿瘤、眼科、自身免疫和代谢疾病领域的单克隆抗体和其他生物药物研发。
Listing Date2018-10-31
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)苏州工业园区东平街168号
Business Address (Hong Kong)香港铜锣湾希慎道33号利园一期19楼1901室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.innoventbio.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 13.98 / shares
Offer Price RangeTo be extracted
Lot Size500 shares
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2018-10-18 to 2018-10-23
Global Offering Shares236,350,000 shares
HK Public Offer Shares (Initial)23,635,000 shares (10.0%)
Public Offer Lots (Initial)47,270lots (Pool A23,635lots,Pool B23,635lots)
International Placing Shares (Initial)212,715,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,118,150,710 shares
Greenshoe (Over-allotment Option)No
Stabilizing Manager (Greenshoe)—
Cornerstone Share58.1%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 3,304,173,000

Stock Connect Inclusion Analysis

HK Market Cap HK$ 152.35B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不适用(公司处于亏损状态)
Profit/Loss Status亏损人民币716.1百万元
Period-End Cash Balance人民币510.5百万元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201620172018-06
Revenue 018,5384,436
Other income and gains, net 33,30764,4067,892
Administrative expenses -52,875-79,490-73,108
Net finance costs -53,799-57,225-32,908
Profit for the year -544,456-716,050-57,596
Profit attributable to owners -504,204-562,31843,894
Balance Sheet
Item 201620172018-06
Cash and cash equivalents 1,012,991510,4711,887,114
Inventories 36,63157,72248,980
Total current assets 1,870,7501,445,7553,837,595
Total assets 2,815,8002,457,2164,893,774
Total current liabilities 76,199163,2761,770,182
Total liabilities 3,774,0184,079,3446,467,649
Total equity -958,218-1,622,128-1,573,875
Equity attributable to owners -1,383,924-1,942,548-1,573,875
Interest-bearing borrowings 500,000510,000697,000
Cash Flow Statement
Item 201620172018-06
Net cash from operating activities -362,993-492,270-342,525
Net cash from investing activities -572,079-349,456525,053
Net cash from financing activities 1,639,60589,4061,119,893
Net increase in cash 704,533-752,3201,302,421
Depreciation of PP&E 53,34759,85330,491
Purchase of PP&E -58,444-90,971-93,470
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 16.58
First Day OpenHK$ 14.3
First Day Change18.60%
First Day Volume46747200.0
First Day Turnover704900000.0
Use of Proceeds
1、52%或約1640.8百萬港元用于撥資正在進行及計劃中的信迪利單抗(IBI-308)臨床試驗、注冊備案的準備事宜及計劃的商業化推出(包括銷售及市場推廣) 2、8%或約252.4百萬港元用于撥資正在進行及計劃中的IBI-305臨床試驗、注冊備案的準備事宜及計劃的商業化推出(包括銷售及市場推廣); 3、4%或約126.2百萬港元用于撥資正在進行及計劃中的IBI-301臨床試驗、注冊備案的準備事宜及計劃的商業化推出(包括銷售及市場推廣); 4、1%或約31.6百萬港元用于撥資正在進行及計劃中的IBI-303臨床試驗、注冊備案的準備事宜及計劃的商業化推出(包括銷售及市場推廣)。 5、25%或約788.8百萬港元用于撥資正在進行及計劃中的其他管線候選藥物的臨床試驗、注冊備案的準備事宜及潛在的商業化推出(包括銷售及市場推廣)。 6、10%或約315.5百萬港元,用作營運資金及一般公司用途。

Underwriting Syndicate

Joint Sponsors (4)
Morgan Stanley Asia Limited CE AAD291 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 J.P. Morgan Securities (Far East) Limited CE AAB026 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Overall Coordinators (5)
Morgan Stanley Asia Limited CE AAD291 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Joint Bookrunners (6)
Morgan Stanley Asia Limited CE AAD291 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 香港上海汇丰银行有限公司 CE AAA523
Joint Lead Managers (6)
Morgan Stanley Asia Limited CE AAD291 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 香港上海汇丰银行有限公司 CE AAA523

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Cormorant Asset Management, LP 195,950,670 HKD — 5.90% — 6 months 2019-04-30
2 Elbrus Investments Pte. Ltd. 156,995,400 HKD — 4.80% — 6 months 2019-04-30
3 LAV Biosciences Fund IV, L.P. 156,757,740 HKD — 4.70% — 6 months 2019-04-30
4 Prime Capital Funds 235,129,620 HKD — 7.10% — 6 months 2019-04-30
5 Rock Springs Capital Master Fund LP 39,185,940 HKD — 1.20% — 6 months 2019-04-30
6 SCC Growth V Holdco L, Ltd. 470,287,200 HKD — 14.20% — 6 months 2019-04-30
7 Seacliff (Cayman) Ltd. 156,757,740 HKD — 4.80% — 6 months 2019-04-30
8 Vivo Funds 117,571,800 HKD — 3.60% — 6 months 2019-04-30
9 惠理基金管理香港有限公司 235,143,600 HKD — 7.10% — 6 months 2019-04-30
10 景林资产管理有限公司 156,757,740 HKD — 4.70% — 6 months 2019-04-30

Directors & Management

PositionChinese nameEnglish Name
Chairman俞德超—
Company Secretary王豔菊、陳濼而—
No director data available.

Major Shareholders

Major Shareholders & Holdings主要股东包括FIL Limited(通过Asia Ventures及F-Prime Capital持有约13.97%)、FMR LLC(通过Impresa Fund III Limited Partnership持有约13.97%)、Capital International Private Equity Fund VI, L.P.(通过Seacliff (Cayman) Ltd.持有约6.00%)、Temasek Holdings (Private) Limited(通过TLS Beta持有约5.77%)、Great Biono Fortune LP(持有约8.06%,由俞德超博士控制)。
About this page

This page shows Innovent Bio (01801) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect